HLA-A*02:01 HPV16 E7 Tetramer-YMLDLQPETT-APC

MBL

Catalog No: MBL-TS-M048-2

The α3 mutation significantly reduces the binding of MHC tetramer to human CD8. To minimizes the aberrant effect of some CD8 antibodies; clone SFCI21Thy2D3 (also known as “T8”) is recommended.

Citations for HLA-A*02:01 HPV16 E7 Tetramer-YMLDLQPETT-APC – 1 Found

Quayle, Steven N; Girgis, Natasha; Thapa, Dharma R; Merazga, Zohra; Kemp, Melissa M; Histed, Alex; Zhao, Fan; Moreta, Miguel; Ruthardt, Paige; Hulot, Sandrine; Nelson, Alyssa; Kraemer, Lauren D; Beal, Dominic R; Witt, Luke; Ryabin, Jessica; Soriano, Jonathan; Haydock, Mark; Spaulding, Emily; Ross, John F; Kiener, Peter A; Almo, Steven; Chaparro, Rodolfo; Seidel, Ronald; Suri, Anish; Cemerski, Saso; Pienta, Kenneth J; Simcox, Mary Ellen. CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research. 2020;26(8):1953-1964.